ReviewPrognostic and predictive biomarkers in breast cancer: Past, present and future
Introduction
Following a diagnosis of invasive breast cancer, one of the most immediate challenges is to identify who should or should not receive adjuvant treatment, especially adjuvant chemotherapy. If the decision is to administer adjuvant therapy, the next challenge is to identify the most suitable therapy or combination of therapies for a given patient. Addressing the first challenge can be aided by prognostic factors/biomarkers while addressing the second challenge can be helped with predictive biomarkers. The aim of this article is to discuss how prognostic and predictive biomarkers help optimize therapy decision making in patients with newly diagnosed breast cancer. First however, we briefly review the contribution of the traditional prognostic factors for the management of patients with early breast cancer.
Section snippets
Traditional prognostic factors
With so much emphasis being placed on molecular prognostic tests in recent years, the important contribution of the traditional clinical/pathological factors (Table 1) tends to be forgotten. Of the factors listed in Table 1, the most widely used are the number of regional lymph nodes with metastases, tumor size and tumor grade [1], [2]. Despite the availability of multiple molecular tests in recent years, these factors continue to be mandatory for determining prognosis and aiding therapy
Molecular prognostic biomarkers
Although the number of lymph node metastases, tumor size and tumor grade all supply independent prognostic information in patients with newly diagnosed breast cancer, it is widely accepted that these factors alone are inadequate for optimum patient management, especially as we move towards the era of personalized treatment [15], [16]. Consequently, in recent years, a substantial amount of research has been devoted to the development and validation of molecular biomarkers that can provide not
Predictive biomarkers
In contrast to prognostic biomarkers which predict the risk of disease recurrence, predictive biomarkers help identify upfront those patients that are likely to respond or be resistant to specific therapies. Of all the common cancers, breast cancer has led the way in the use of therapy predictive biomarkers. For example, the measurement of estrogen and progesterone receptors (ER, PR) to predict response to endocrine therapy entered clinical use over 40 years ago while measurement of HER2 for
The need for development of an advanced technology: DNA and RNA genotyping techniques
Due to the genetic and epigenetic origin of cancer the need for more rapidly and accurately sequencing DNA and RNA and to better investigate the transcriptional machinery has strongly emerged. In a relatively short time huge progress in the available techniques as well as the related computational biology has been made. All these techniques which have been applied to samples from tissue and recently from peripheral blood (PB) samples as well have had a great impact in discovering at genetic and
Investigational prognostic and predictive biomarkers
In the last years, many investigations using the new techniques have been carried out. In tissue the expression of single or multiple (genetic signature) genes or single or multiple (cluster, micro-RNA signature) micro-RNAs (mi-RNAs) and in peripheral blood (PB) mi-RNAs, circulating tumor cells (CTCs) and circulating tumor DNA (ct DNA) have been detected. Moreover, in serum/plasma miRNAs benefit from the advantage to be highly stable [119]. In some instances, databases have been a helpful tool
Challenges for future research
Although substantial progress has been made in the identification and validation of prognostic and predictive biomarkers for breast, several major challenges remain. These include identification and validation of biomarkers for:
- -
Predicting response to specific forms of chemotherapy.
- -
Identifying patients likely to develop severe chemotherapy-related toxicity.
- -
Predicting response to radiotherapy.
- -
Enhancing the positive predictive value of ER.
- -
Selecting patients that preferentially benefit from an
Conclusion
Breast cancer has led the way in the introduction of prognostic and predictive biomarkers for cancer patients. Over 40 years ago, ER was first introduced for predicting response to endocrine therapy. Twenty years later, HER2 became available for identifying patients likely to benefit from trastuzumab and later to other forms of anti-HER2 therapy. In the last decade, several multigene signatures have been proposed for identifying patients with early breast cancer whose prognosis is so good, that
Conflicts of interest
MJD is a clinical advisor to OncoMark and Atturos.
Acknowledgements
MJD wishes to thank Science Foundation Ireland, Strategic Research Cluster Award (08/SRC/B1410) to Molecular Therapeutics for Cancer Ireland (MTCI), the BREAST-PREDICT (CCRC13GAL) program of the Irish Cancer Society and the Clinical Cancer Research Trust for funding his work.
References (279)
- et al.
Predictors of 5-year local, regional, and distant recurrent events in a population-based cohort of breast cancer patients
Am. J. Surg.
(2017) - et al.
Histological grading of breast carcinomas: a study of interobserver agreement
Hum. Pathol.
(1995) - et al.
Validated biomarkers: the key to precision treatment in patients with breast cancer
Breast
(2016) - et al.
Clinical use of biomarkers in breast cancer: updated guidelines from the European group on tumor markers (EGTM)
Eur. J. Cancer
(2017) - et al.
Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up ESMO guidelines committee
Ann. Oncol.
(2015) - et al.
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer
Eur. J. Cancer
(2016) - et al.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
Lancet Oncol.
(2007) - et al.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
Lancet Oncol.
(2007) - et al.
Ten-year analysis of the prospective multicenter Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
Eur. J. Cancer
(2013) - et al.
Ki67 assessment in breast cancer: an update
Pathology
(2017)
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
Mod. Pathol.
Clinical utility of cytokeratins as tumor markers
Clin. Biochem.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Lancet
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
Ann. Oncol.
Progesterone receptor is a significant factor associated with clinical outcome and effect of adjuvant tamoxifen therapy in breast cancer patients
Breast Cancer Res. Treat.
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage
Breast
HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials
Cancer Res Treat
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Lancet Oncol.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Lancet Oncol.
Herceptin Adjuvant (HERA) Trial Study Team: 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Lancet
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Cancer Cell
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Ann. Oncol.
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
Ann. Oncol.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Ann. Oncol.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Ann. Oncol.
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Pathology (Phila.)
Prognostic and predictive factors in early-stage breast cancer
Oncologist
Tumor-related prognostic factors for breast cancer
CA. Cancer J. Clin.
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Cancer
Molecular testing in breast cancer
Annu. Rev. Med.
Method for grading breast cancer
J. Clin. Pathol.
Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma
Histopathology
Applying the nottingham prognostic index to a swedish breast cancer population. South East Swedish breast cancer study group
Breast Cancer Res. Treat.
Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast
Breast Cancer Res. Treat.
Breast cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual
CA. Cancer J. Clin.
Histologic grading of breast carcinoma. A reproducibility study
Cancer
Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma
Am. J. Clin. Pathol.
Genomic grade index: an important tool for assessing breast cancer tumor grade and prognosis
Crit. Rev. Oncol. Hematol.
Use of multiparameter tests for identifying women with early breast cancer who do not need adjuvant chemotherapy
Clin. Chem.
American Society of Clinical Oncology: use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline
J. Clin. Oncol.
NCCN Guidelines, Breast Cancer. V.2
A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer
N. Engl. J. Med.
Clinical evidence supporting genomic tests in early breast cancer: do all genomic tests provide the same information?
Eur. J. Surg. Oncol.
Prospective validation of a 21-gene expression assay in breast cancer
N. Engl. J. Med.
The WSG phase III planB trial: first prospective outcome data for the 21-gene Recurrence Score Assay and concordance of prognostic markers by central and local pathology assessment
J. Clin. Oncol.
Gene expression and benefit of chemotherapy in women with node-negative, ER-positive breast cancer
J. Clin. Oncol.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Lancet Oncol.
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses
Breast Cancer Res. Treat.
A gene expression signature as a predictor of survival in breast cancer
N. Engl. J. Med.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
J. Natl. Cancer Inst.
Cited by (283)
Research progress of LSD1-based dual-target agents for cancer therapy
2024, Bioorganic and Medicinal ChemistryRoutine molecular applications and recent advances in breast cancer diagnostics
2024, Journal of BiotechnologyProteomic-based electrochemical non-invasive biosensor for early breast cancer diagnosis
2023, International Journal of Biological MacromoleculesCopper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer
2024, Clinical Medicine Insights: Oncology